BRIEF-Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285

* Blueprint Medicines announces proof-of-concept data from

Phase 1 clinical trial of BLU-285 in patients with advanced

gastrointestinal stromal tumors

Read more